©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Aug 7, 2025; 31(29): 109090
Published online Aug 7, 2025. doi: 10.3748/wjg.v31.i29.109090
Published online Aug 7, 2025. doi: 10.3748/wjg.v31.i29.109090
Gut-liver axis in diabetes: Mechanisms and therapeutic opportunities
Mona Mohamed Ibrahim Abdalla, Department of Human Biology, School of Medicine, Inter
Author contributions: Abdalla MMI performed the research and wrote the paper.
Conflict-of-interest statement: The author has no conflict of interest to declare.
Corresponding author: Mona Mohamed Ibrahim Abdalla, MD, PhD, Department of Human Biology, School of Medicine, International Medical University, No. 126 Jln Jalil Perkasa 19, Bukit Jalil 57000, Kuala Lumpur, Malaysia. monamohamed@imu.edu.my
Received: April 29, 2025
Revised: June 3, 2025
Accepted: July 8, 2025
Published online: August 7, 2025
Processing time: 98 Days and 15.1 Hours
Revised: June 3, 2025
Accepted: July 8, 2025
Published online: August 7, 2025
Processing time: 98 Days and 15.1 Hours
Core Tip
Core Tip: Disruption of the gut-liver axis plays a critical role in the pathophysiology of diabetes by linking gut microbiota alterations, intestinal barrier dysfunction, and inflammatory pathways to hepatic insulin resistance and impaired glucose metabolism. Understanding these mechanisms opens new therapeutic opportunities, including microbiota modulation, gut barrier reinforcement, and targeted anti-inflammatory strategies. These approaches have the potential to significantly improve diabetes management and metabolic outcomes.